Daniel Haller
Overview
Explore the profile of Daniel Haller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jin Z, Dixon J, Fiskum J, Parekh H, Sinicrope F, Yothers G, et al.
J Natl Cancer Inst
. 2021 Aug;
113(12):1693-1704.
PMID: 34405233
Background: Colon cancer (CC) incidence in young adults (age 20-49 years), termed early-onset CC (EO-CC), is increasing. Methods: Individual patient data on 35 713 subjects with stage III colon cancer...
2.
Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, et al.
J Clin Oncol
. 2020 Dec;
39(6):642-651.
PMID: 33356421
Purpose: In patients with stage III colon cancer (CC) whose tumors demonstrate microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without oxaliplatin has not been clearly demonstrated...
3.
Lineberry N, Berlin J, Mansi B, Glasser S, Berkwits M, Klem C, et al.
BMJ
. 2016 Oct;
355:i5078.
PMID: 27697753
No abstract available.
4.
Schmoll H, Twelves C, Sun W, OConnell M, Cartwright T, Mckenna E, et al.
Lancet Oncol
. 2014 Dec;
15(13):1481-1492.
PMID: 25456367
Background: Oxaliplatin-based adjuvant therapy is the standard of care for stage III colon cancer. Adjuvant capecitabine with or without oxaliplatin versus leucovorin and fluorouracil with or without oxaliplatin has not...
5.
Biancuzzi G, Haller D, Lemke T, Wischke M, Goldschmidtboeing F, Woias P
IEEE Trans Ultrason Ferroelectr Freq Control
. 2011 Apr;
58(4):689-97.
PMID: 21507746
We present a linearization circuit based on a capacitive Wheatstone bridge that is able to set a desired polarization in a piezoactuator. The system is meant to be used for...
6.
Albert M, Kiefer M, Sun W, Haller D, Fraker D, Tuite C, et al.
Cancer
. 2010 Sep;
117(2):343-52.
PMID: 20830766
Background: Unresectable colorectal liver metastases have a 1- and 2-year survival of 55% and 33% with current systemic therapies. The authors evaluated response and survival after transarterial chemoembolization. Methods: Chemoembolization...
7.
Thomas M, Jaffe D, Choti M, Belghiti J, Curley S, Fong Y, et al.
J Clin Oncol
. 2010 Aug;
28(25):3994-4005.
PMID: 20679622
Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the...
8.
Seitzer U, Gerber S, Beyer D, Dobschanski J, Kullmann B, Haller D, et al.
Parasitol Res
. 2010 Feb;
106(5):1085-102.
PMID: 20162433
Intracellular leukoproliferative Theileria are unique as eukaryotic organisms that transform the immune cells of their ruminant host. Theileria utilize the uncontrolled proliferation for rapid multiplication and distribution into host daughter...
9.
Manne S, Coups E, Winkel G, Markowitz A, Meropol N, Lesko S, et al.
Health Educ Res
. 2009 Aug;
24(5):897-908.
PMID: 19654222
Although first-degree relatives of colorectal cancer (CRC) patients diagnosed at an early age are at increased risk for CRC, their compliance with colorectal cancer screening (CRCS) is not high. Relatively...
10.
Poplin E, Feng Y, Berlin J, Rothenberg M, Hochster H, Mitchell E, et al.
J Clin Oncol
. 2009 Jul;
27(23):3778-85.
PMID: 19581537
Purpose: Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to...